Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases

Joseph Dodson, Peter A. Lio*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Purpose of Review: Biologics and small molecule inhibitors (SMIs) are a rapidly growing class of highly efficacious therapies in the treatment of chronic immunologic and allergic conditions. With precision targeting of inflammatory signaling molecules, these new agents selectively modulate the immune system to treat a variety of conditions. Dermatologic diseases, including atopic dermatitis and psoriasis, are of particular interest due to the growing number of new biologics and SMIs in recent years. This review serves to summarize and evaluate the recent literature regarding biologics and SMIs. Recent Findings: Currently approved biologics for AD achieve clear or almost clear skin in less than 40% of patients treated. Several biologics that are still under investigation for AD have shown better efficacy in phase III trials with similar safety profiles. Recently approved SMIs for AD also demonstrate a high degree of efficacy, but safety profiles may limit their use. Psoriasis has several highly efficacious biologics on the market; however, only one SMI is currently available. Additional SMIs for psoriasis have completed phase III trials and demonstrated high efficacy. Summary: This article evaluates recent literature on biologics and small molecule inhibitors for AD and psoriasis.

Original languageEnglish (US)
Pages (from-to)183-193
Number of pages11
JournalCurrent allergy and asthma reports
Issue number12
StatePublished - Dec 2022


  • Atopic dermatitis
  • Biologics
  • Psoriasis
  • Small molecule inhibitors

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases'. Together they form a unique fingerprint.

Cite this